CClinicalTrials.gg
WithdrawnNCT03295656Updated Jul 17, 2020

Contrast-Enhanced Ultrasound Diagnosis of Acute Appendicitis

A Phase 1 interventional study of Sulfur hexafluoride lipid-type A microspheres in Appendicitis Acute, sponsored by Boston Children's Hospital. Withdrawn at 1 site in United States. Open to participants aged 8 Years to 17 Years. Per ClinicalTrials.gov, last updated 2020-07-17.

Sponsored by Boston Children's Hospital · Phase 1, Interventional, and Diagnostic

Why this study was withdrawn
Unanticipated delays.
Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
8 Years to 17 Years
Sex
All
01

Study summary

This study evaluates the ability of contrast-enhanced ultrasound to improve the diagnosis of acute appendicitis in children compared to conventional ultrasound.

Read the detailed description

Acute appendicitis is the most common surgical emergency in children. Diagnostic evaluation for possible appendicitis frequently leads to imaging studies. Magnetic resonance imaging (MRI) and computed tomography (CT) are currently the gold-standard techniques for the diagnosis or exclusion of acute appendicitis. However, these methods not always immediately available; may require administration of intravenous contrast material with the potential for allergic reactions and nephrotoxicity; and, in the case of CT, requires the administration of ionizing radiation that is linked to the long-term development of radiation-induced cancers. The current study will evaluate a potentially safer, radiation-free diagnostic method for acute appendicitis, using contrast-enhanced ultrasound to provide a more accurate means of visualizing the appendix than conventional US imaging.

02

Conditions studied

  • Appendicitis Acute

Browse trials for

03

Who can participate

Ages eligible
8 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Children who have had a conventional abdominal US study to rule out acute appendicitis and are scheduled for an MRI or CT examination.

Exclusion criteria

Exclusion Criteria:

  • Children with serious comorbid conditions, including but not restricted to severe cardiac, pulmonary, renal, or hepatic disease; prior bone marrow or solid organ transplant; cancer; or presence of a ventriculoperitoneal shunt.
  • Children with an allergy to either the active or inactive components of Lumason.
  • Pregnant or nursing patients.
04

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    IV Contrast-Enhanced US

    IV sulfur hexafluoride lipid-type A microspheres, 0.03 mL/kg, 2 doses per examination, total dose not to exceed 4.8 mL. Single examination per patient.

    Drug: Sulfur hexafluoride lipid-type A microspheres

Interventions

  • DrugSulfur hexafluoride lipid-type A microspheres

    Contrast-enhanced US imaging of the appendix

    Also known as: Lumason

05

What researchers measure

Primary outcomes

  1. Contrast-enhanced ultrasound diagnosis of acute appendicitis

    The efficacy of contrast-enhanced US in improving the diagnosis of acute appendicitis compared to conventional US will be assessed.

    Time frame: One week

06

Study locations

1 site
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03295656
Lead sponsor
Boston Children's Hospital
Responsible party
Harriet Joan Paltiel (Associate Professor of Radiology, Boston Children's Hospital) — Principal investigator
First posted
Sep 28, 2017
Start date
Jul 15, 2020
Primary completion
Jul 15, 2020
Completion
Jul 15, 2020
Last update
Jul 17, 2020

Study contacts

Harriet Paltiel, MDCM
principal investigator · Boston Children's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion